Thermo Fisher CEO Marc N. Casper Highlights Strong Q3 2024 Results with $10.6 Billion Revenue and Breakthrough Innovations

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the third quarter ended September 28, ...

October 24, 2024 | Thursday | Company results
Florida Lung Health Coalition and DELFI Diagnostics Launch Initiative to Transform Lung Cancer Screening

In a groundbreaking alliance announced, the Florida Lung Health Coalition and DELFI Diagnostics, supported by RadNet, Inc. (NASDAQ: RDNT), and the Ame...

October 23, 2024 | Wednesday | News
Grifols Partners with BARDA to Develop Eye Drops for Sulfur Mustard Ocular Injury

Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, announced it has established a...

October 23, 2024 | Wednesday | News
Biogen to Showcase Promising Data on Felzartamab at Kidney Week 2024

Biogen Inc. (Nasdaq: BIIB) – announced the company will present a variety of new data from its felzartamab clinical development program at Kidne...

October 23, 2024 | Wednesday | News
Sanofi and CD&R Announce Exclusive Negotiations for 50% Stake in Opella, Poised to Create Global Consumer Healthcare Leader

 Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. S...

October 22, 2024 | Tuesday | News
Ionis and AstraZeneca's WAINZUA Recommended for EU Approval for Hereditary Amyloidosis Treatment

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for approval by the Comm...

October 22, 2024 | Tuesday | News
Agilent Technologies Introduces Next-Generation InfinityLab LC Series with Innovative Assist Technology, Transforming Lab Automation and Efficiency

Agilent Technologies Inc. (NYSE: A) announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infi...

October 22, 2024 | Tuesday | News
Catalent CEO John Chiminski Issues Open Letter Addressing Novo Holdings’ Acquisition and Reaffirms Commitment to Customers

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, issued the following open lette...

October 22, 2024 | Tuesday | News
BOTOX® Cosmetic Gains FDA Approval for Treatment of Platysma Bands, Expanding Aesthetic Options Beyond the Face

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the appearanc...

October 21, 2024 | Monday | News
Novartis’ Kisqali Receives Positive CHMP Opinion for Adjuvant Treatment of High-Risk Early Breast Cancer

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and...

October 21, 2024 | Monday | News
MSD and Gilead Announce Promising Results for Once-Weekly HIV Treatment in Phase 2 Study

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced new results from a Phase 2 clin...

October 21, 2024 | Monday | News
Antengene Secures South Korean Approval for XPOVIO® in Combination Therapy for Multiple Myeloma

SHANGHAI and HONG KONG, Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmac...

October 18, 2024 | Friday | News
AbbVie Receives FDA Approval for VYALEV™: First Continuous Subcutaneous Infusion Therapy for Advanced Parkinson's Disease

AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and o...

October 18, 2024 | Friday | News
MSD's Clesrovimab Shows Promising Results in Protecting Infants from RSV in Phase 2b/3 Trial

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of positive results from the Phase 2b/3 clinical trial ...

October 18, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close